Basic Information
| LncRNA/CircRNA Name | LINC01125 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Cisplatin | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | ovarian cancer |
| ICD-0-3 | C56.9 |
| Methods | qRT-PCR, Dual luciferase reporter assay, RIP |
| Sample | OC tissues,CDDP-resistant OC cell lines (SKOV-3/CDDP and A2780/CDDP) and their parental OC lines (SKOV-3 and A2780) |
| Expression Pattern | down-regulated |
| Function Description | LINC01125 expression was significantly downregulated in CDDP-resistant OC tissues and cell lines. Overexpression of LINC01125 inhibited OC cell proliferation and enhanced the cytotoxicity of CDDP in OC cells. Additionally, LINC01125 participated in the apoptosis pathway by directly binding to miR-1972 in OC cells. |
| Pubmed ID | 31865363 |
| Year | 2019 |
| Title | Long Noncoding RNA LINC01125 Enhances Cisplatin Sensitivity of Ovarian Cancer via miR-1972 |
External Links
| Links for LINC01125 | GenBank HGNC NONCODE |
| Links for ovarian cancer | OMIM COSMIC |